Compare NIU & PBYI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | NIU | PBYI |
|---|---|---|
| Founded | 2014 | 2010 |
| Country | China | United States |
| Employees | N/A | N/A |
| Industry | Auto Manufacturing | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 275.6M | 263.4M |
| IPO Year | 2018 | N/A |
| Metric | NIU | PBYI |
|---|---|---|
| Price | $3.11 | $6.39 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 1 |
| Target Price | N/A | ★ $7.00 |
| AVG Volume (30 Days) | ★ 681.2K | 368.1K |
| Earning Date | 11-17-2025 | 02-26-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 59.87 |
| EPS | N/A | ★ 0.74 |
| Revenue | ★ $625,182,280.00 | $211,995,000.00 |
| Revenue This Year | $42.51 | N/A |
| Revenue Next Year | $23.71 | N/A |
| P/E Ratio | ★ N/A | $8.56 |
| Revenue Growth | ★ 50.99 | N/A |
| 52 Week Low | $1.75 | $2.58 |
| 52 Week High | $5.67 | $6.48 |
| Indicator | NIU | PBYI |
|---|---|---|
| Relative Strength Index (RSI) | 43.18 | 64.96 |
| Support Level | $3.12 | $6.05 |
| Resistance Level | $3.30 | $6.29 |
| Average True Range (ATR) | 0.15 | 0.23 |
| MACD | 0.01 | 0.02 |
| Stochastic Oscillator | 20.45 | 86.12 |
Niu Technologies designs, manufactures and sells high-performance electric motorcycles, scooters, bicycles, and kick-scooters. The company has a product portfolio consisting of electric motorcycle, mopeds and bicycle series, including the NQi, MQi, UQi, F series, and others, and micro-mobility series, including the kick-scooter series KQi and the e-bike series BQi. The company's principal operations and geographic markets are predominantly in the People's Republic of China. It also generates revenue from Europe and other regions.
Puma Biotechnology Inc is a biopharmaceutical company that develops and commercializes inventive products to enhance cancer care and improve treatment outcomes for patients. It is currently commercializing NERLYNX, an oral version of neratinib, for the treatment of HER2-positive breast cancer. Also it develops alisertib. Alisertib is a selective, small-molecule inhibitor of aurora kinase A that is designed to disrupt mitosis resulting into apoptosis of rapidly proliferating tumor cells that are dependent on aurora kinase A.